Curio Bioscience v 10x Genomics (CoA, 17 April 2024)
| Date | 17 April 2024 |
|---|---|
| Court | CoA |
| Division | Luxembourg (LU) |
| Type of action | Appeal RoP220.1 |
| Registry reference | APL_12116/2024 · ORD_18194/2024 |
| Parties | Curio Bioscience Inc. v. 10x Genomics, Inc. |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By order of 17 April 2024 (UPC_CoA_101/2024), the Court of Appeal set aside the order of the President of the Court of First Instance of 26 February 2024 and determined English, the language of EP 2 697 391, as the language of the provisional measures proceedings brought in German by 10x Genomics against Curio Bioscience before the Düsseldorf Local Division. The order, which carries a headnote, sets out how fairness under Article 49(5) UPCA is to be assessed: the circumstances of the case and of the parties come first, in particular the defendant’s position, which is decisive where the interests are evenly balanced.
Question
Is a change of the language of proceedings to the language of the patent, requested by the defendant, justified on grounds of fairness?
Decision
Although review of the President’s discretion is limited, the order was set aside for misinterpreting fairness (paragraphs 18 to 20). Relevant factors include the language commonly used in the technical field and that of the main evidence. The representatives’ language skills and the judges’ nationality are in principle irrelevant (paragraphs 21 to 23, 26 and 27). Curio is clearly smaller than 10x, so there was no need to decide whether it is an SME (paragraphs 24 and 38). A claimant, who chooses the court and the timing of the action, must expect to proceed in the language of the patent (paragraphs 29 to 34). Both companies being American, and the technology and most of the evidence being in English, the defendant’s interest prevailed (paragraphs 37, 39 and 43). If the order on provisional measures is appealed, the parties must file uncertified English translations of their pleadings at their own cost (Rule 7.2 RoP).
Key points for practice
- Where the interests are evenly balanced, the defendant’s position is decisive for a switch to the language of the patent (headnote and paragraphs 37 to 43).
- The relative size of the parties and the language of the technology and of the evidence carry more weight than the language skills of counsel (paragraphs 21 to 27).
Provisions applied
- Agreement on a Unified Patent Court
- Arts 49(1), (2), (3), (5) and (6), 50, 52(1), 69 and 74(3)
- Rules of Procedure
- Rules 7.2, 14.2, 118.5, 150, 152.2, 225, 242.1 and 323
- European Patent Convention
- Art. 14(8)
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Going further
Lexicon: UPC Court of Appeal.
Dhenne Avocats blog: UPC Appeals: What the Numbers Show.
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Proceedings
Parties
- defendant10x Genomics, Inc.57 decisions in the corpusFollow this party
- claimantCurio Bioscience Inc.29 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Appeal RoP220.1
- Outcome (Dhenne Avocats summary)
- La cour d'appel infirme le refus du président du tribunal de première instance et fixe l'anglais comme langue de la procédure de mesures provisoires, l'équité commandant de privilégier la situation de la défenderesse.
- Appeal
- Decision of the Court of Appeal.
- Instance
- Court of Appeal decision.
Patents mentioned
EP 2 697 391mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- In(k)control v Esko-Software (CFI, 27 April 2026) cites this decision
- Bobst Manchester v Nordmeccanica (CFI, 26 January 2026) cites this decision
- Nagravision v Pinterest Germany (CFI, 20 January 2026) cites this decision
- Huawei Technologies v TP-Link Systems (CFI, 18 November 2025) cites this decision
- FAST IP v Skechers USA Deutschland (CFI, 29 October 2025) cites this decision
- Huawei Technologies v HMD Global (CFI, 12 September 2025) cites this decision
- Fraunhofer-Gesellschaft v HMD Global (CFI, 8 September 2025) cites this decision
- Husqvarna v POSITEC Germany (CFI, 16 July 2025) cites this decision
- InterDigital VC Holdings v The Walt Disney Company (CFI, 9 July 2025) cites this decision
- InterDigital CE Patent Holdings v The Walt Disney Company (CFI, 18 June 2025) cites this decision
- InterDigital VC Holdings v The Walt Disney Company (CFI, 2 May 2025) cites this decision
- InterDigital VC Holdings v The Walt Disney Company (CFI, 30 April 2025) cites this decision
- BF exaQC v NVIDIA (CFI, 16 January 2025) cites this decision
- Google Commerce v Ona Patents (CoA, 18 September 2024) cites this decision
- Apple Retail Germany v Ona Patents (CoA, 18 September 2024) cites this decision
- Advanced Bionics v MED-EL Elektromedizinische Geräte Gesellschaft m.b.H. (CoA, ORD_42779/2024, 5 September 2024) cites this decision
- Maxeon Solar v Aiko Energy Germany (CFI, 23 August 2024) cites this decision
- Roche Diabetes Care v Tandem Diabetes Care (CFI, 26 July 2024) cites this decision
- 10x Genomics v Curio Bioscience (CoA, 5 July 2024) cites this decision
- Ona Patents v Apple Retail Germany (CFI, 18 June 2024) cites this decision
- Ona Patents v Google Ireland (CFI, 18 June 2024) cites this decision
- Headwater Research v Samsung Electronics (CFI, 30 May 2024) cites this decision
- Curio Bioscience v 10x Genomics (CFI, 23 April 2024) cites this decision
- Esko-Graphics v In(k)control (CoA, 8 October 2026) cites this decision
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 2 697 391Method and product for localised or spatial detection of nucleic acid in a tissue sample recorded proprietor: Spatial Transcriptomics AB | Mentioned in the analysis (role not qualified) Also mentioned in 28 other decision(s): 10x Genomics v Curio Bioscience (CFI, ORD_598272/2023, 30 April 2024) · 10x Genomics v Curio Bioscience (CFI, UPC_CFI_658/2025, 2 February 202 · 10x Genomics v Curio Bioscience (CFI, UPC_CFI_657/2025, 2 February 202 · 10x Genomics v Curio Bioscience (CFI, 5 August 2025) · 10x Genomics v Curio Bioscience (CFI, 4 August 2025) · 10x Genomics v Curio Bioscience (CFI, 16 June 2025) · 10x Genomics v Curio Bioscience (CFI, 4 June 2025) · 10x Genomics v Curio Bioscience (CFI, 2 May 2025) | not recorded | not recorded | not recorded | Espacenet · European Patent Register existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically) mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.